Literature DB >> 8566958

A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2.

L Kluwe1, V F Mautner.   

Abstract

Since the identification of the NF2 tumor suppressor gene in 1993, various mutations have been found in NF2-related tumors and in lymphocytes from NF2 patients. Most of the reported mutations result in truncated gene products. Missense mutations affecting the tumor suppressor are rare. These missense mutations would provide valuable information for the understanding of the function of the tumor suppressor, since they should affect critical parts of the protein. In this study we describe a novel point mutation in exon 15 of the NF2 gene, which is found in lymphocyte DNA of two NF2 patients from one family. This mutation is expected to result in a substitution of Pro for Gln at codon 538. Though both of the two patients developed bilateral vestibular schwannomas, the first patient showed onset of the disease at the age of 31 years and presented with various central, peripheral and abdominal tumors, while the second patient showed later onset of clinical symptoms (at age 52 years) and presented with only two additional small spinal tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566958     DOI: 10.1007/bf02265270

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  22 in total

1.  Germline mutations in the neurofibromatosis type 2 tumour suppressor gene.

Authors:  D Bourn; S A Carter; S Mason; D Gareth; R Evans; T Strachan
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

2.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.

Authors:  D F Easton; M A Ponder; S M Huson; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

3.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

4.  A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.

Authors:  D Bourn; S A Carter; D G Evans; J Goodship; H Coakham; T Strachan
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

5.  Exon scanning for mutation of the NF2 gene in schwannomas.

Authors:  L B Jacoby; M MacCollin; D N Louis; T Mohney; M P Rubio; K Pulaski; J A Trofatter; N Kley; B Seizinger; V Ramesh
Journal:  Hum Mol Genet       Date:  1994-03       Impact factor: 6.150

6.  Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Authors:  R H Lekanne Deprez; A B Bianchi; N A Groen; B R Seizinger; A Hagemeijer; E van Drunen; D Bootsma; J W Koper; C J Avezaat; N Kley
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

7.  Mutational analysis of patients with neurofibromatosis 2.

Authors:  M MacCollin; V Ramesh; L B Jacoby; D N Louis; M P Rubio; K Pulaski; J A Trofatter; M P Short; C Bove; R Eldridge
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

8.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

9.  Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas.

Authors:  J Sainz; D P Huynh; K Figueroa; N K Ragge; M E Baser; S M Pulst
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

10.  Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.

Authors:  R M Irving; D A Moffat; D G Hardy; D E Barton; J H Xuereb; E R Maher
Journal:  Hum Mol Genet       Date:  1994-02       Impact factor: 6.150

View more
  7 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression.

Authors:  Vinay Mandati; Laurence Del Maestro; Florent Dingli; Bérangère Lombard; Damarys Loew; Nicolas Molinie; Stephane Romero; Daniel Bouvard; Daniel Louvard; Alexis M Gautreau; Eric Pasmant; Dominique Lallemand
Journal:  J Biol Chem       Date:  2019-07-11       Impact factor: 5.157

3.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

Authors:  D M Parry; M M MacCollin; M I Kaiser-Kupfer; K Pulaski; H S Nicholson; M Bolesta; R Eldridge; J F Gusella
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

4.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

5.  The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas.

Authors:  Cailei Zhao; Qian Chen; Chunde Li; Jian Yang; Cong Li; Yangyang Zhou; Jianxiang Liao
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

6.  Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity.

Authors:  Minja Laulajainen; Maria Melikova; Taru Muranen; Olli Carpén; Mikaela Grönholm
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

Review 7.  Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Authors:  M Ruggieri; A D Praticò; A Serra; L Maiolino; S Cocuzza; P Di Mauro; L Licciardello; P Milone; G Privitera; G Belfiore; M Di Pietro; F Di Raimondo; A Romano; A Chiarenza; M Muglia; A Polizzi; D G Evans
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-10       Impact factor: 2.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.